<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11125637</article-id><article-id pub-id-type="pmcid-ver">PMC11125637.1</article-id><article-id pub-id-type="pmcaid">11125637</article-id><article-id pub-id-type="pmcaiid">11125637</article-id><article-id pub-id-type="pmid">38793735</article-id><article-id pub-id-type="doi">10.3390/vaccines12050484</article-id><article-id pub-id-type="publisher-id">vaccines-12-00484</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Targeting <italic toggle="yes">Plasmodium</italic> Life Cycle with Novel Parasite Ligands as Vaccine Antigens</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Khan</surname><given-names initials="S">Shan</given-names></name><xref rid="fn1-vaccines-12-00484" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Patel</surname><given-names initials="MP">Manas Paresh</given-names></name><xref rid="fn1-vaccines-12-00484" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Patni</surname><given-names initials="AD">Aleem Damji</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cha</surname><given-names initials="SJ">Sung-Jae</given-names></name><xref rid="c1-vaccines-12-00484" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Shakri</surname><given-names initials="AR">Ahmad R.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Raj</surname><given-names initials="D">Dipak</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-00484">Department of Medical Sciences, Mercer University School of Medicine, 1501 Mercer University Drive, Macon, GA 31207, USA; <email>shan.khan@live.mercer.edu</email> (S.K.); <email>manas.paresh.patel@live.mercer.edu</email> (M.P.P.); <email>aleem.damji.patni@live.mercer.edu</email> (A.D.P.)</aff><author-notes><corresp id="c1-vaccines-12-00484"><label>*</label>Correspondence: <email>cha_s@mercer.edu</email>; Tel.: +1-478-301-4004</corresp><fn id="fn1-vaccines-12-00484"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>4</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2024</year></pub-date><volume>12</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">463298</issue-id><elocation-id>484</elocation-id><history><date date-type="received"><day>28</day><month>3</month><year>2024</year></date><date date-type="rev-recd"><day>28</day><month>4</month><year>2024</year></date><date date-type="accepted"><day>30</day><month>4</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>04</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>25</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-26 07:25:15.357"><day>26</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-12-00484.pdf"/><abstract><p>The WHO reported an estimated 249 million malaria cases and 608,000 malaria deaths in 85 countries in 2022. A total of 94% of malaria deaths occurred in Africa, 80% of which were children under 5. In other words, one child dies every minute from malaria. The RTS,S/AS01 malaria vaccine, which uses the <italic toggle="yes">Plasmodium falciparum</italic> circumsporozoite protein (CSP) to target sporozoite infection of the liver, achieved modest efficacy. The Malaria Vaccine Implementation Program (MVIP), coordinated by the WHO and completed at the end of 2023, found that immunization reduced mortality by only 13%. To further reduce malaria death, the development of a more effective malaria vaccine is a high priority. Three malaria vaccine targets being considered are the sporozoite liver infection (pre-erythrocytic stage), the merozoite red blood cell infection (asexual erythrocytic stage), and the gamete/zygote mosquito infection (sexual/transmission stage). These targets involve specific ligand-receptor interactions. However, most current malaria vaccine candidates that target two major parasite population bottlenecks, liver infection, and mosquito midgut infection, do not focus on such parasite ligands. Here, we evaluate the potential of newly identified parasite ligands with a phage peptide-display technique as novel malaria vaccine antigens.</p></abstract><kwd-group><kwd>malaria</kwd><kwd>ligand-receptor interaction</kwd><kwd>phage display</kwd><kwd>vaccine target</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-00484"><title>1. Introduction</title><p>Malaria is the deadliest known vector-borne infectious disease. Malaria can be controlled by killing mosquitoes with insecticides, drug treatment of patients, and vaccination of humans. Although insecticides and drugs have reduced malaria death, this approach faces difficulties due to a selection of resistant mosquitoes and parasites. Moreover, an effective malaria vaccine is yet to be implemented. The malaria parasite has a complex life cycle with multiple stages in the mosquito and in humans, with each step involving specific host cell recognition. Therefore, targeting the [parasite ligand-host cell receptor] pair is a prime goal of malaria vaccine development.</p><p>Human infection starts with the release of ~50 sporozoites into the human skin by the bite of an infected <italic toggle="yes">Anopheles</italic> mosquito [<xref rid="B1-vaccines-12-00484" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-12-00484" ref-type="bibr">2</xref>]. Sporozoites enter the blood circulation and move to the first target organ, the liver. Circulating sporozoites are retained by the liver via electrostatic interaction between the positively charged CSP protein that covers the sporozoite surface and the negatively charged glycosaminoglycans (GAGs) produced by Stellate cells in the liver parenchyma and protruding through the fenestrations of the liver sinusoidal (blood vessel) lining [<xref rid="B3-vaccines-12-00484" ref-type="bibr">3</xref>]. Next, sporozoites traverse the liver sinusoidal lining by invading macrophage-like Kupffer cells or endothelial cells [<xref rid="B4-vaccines-12-00484" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-12-00484" ref-type="bibr">5</xref>], followed by an invasion of a hepatocyte to establish a productive infection. Although only a few sporozoites reach their destination, each infected liver cell generates around 30,000 hepatic merozoites which are released into the blood circulation where they proliferate and cause pathogenesis [<xref rid="B2-vaccines-12-00484" ref-type="bibr">2</xref>,<xref rid="B6-vaccines-12-00484" ref-type="bibr">6</xref>]. Sporozoite liver infection constitutes the most dramatic malaria parasite population bottleneck and has been a focus of malaria vaccine development. The most advanced malaria vaccine RTS,S/AS01 targets the sporozoite CSP, which is essential for liver infection [<xref rid="B7-vaccines-12-00484" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-00484" ref-type="bibr">8</xref>]. Malaria vaccines that target liver infection (before RBC infection) are called pre-erythrocytic vaccines (PEV), and vaccines that target asexual blood-stage parasite antigens, mainly on the merozoites surface, are called blood-stage vaccines (BSV). Since the blood stage starts with the release of a large number of hepatic merozoites, followed by quick (30~70 s) invasion of RBCs utilizing redundant ligand-receptor pairs [<xref rid="B9-vaccines-12-00484" ref-type="bibr">9</xref>], the development of blood-stage vaccines is more challenging. Indeed, no sterile protection has been reported from human BSV trials [<xref rid="B7-vaccines-12-00484" ref-type="bibr">7</xref>]. In addition to liver infection, another parasite population bottleneck occurs at the initial stages of mosquito infection [<xref rid="B10-vaccines-12-00484" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-12-00484" ref-type="bibr">11</xref>]. In an infected human, less than 5% of <italic toggle="yes">Plasmodium</italic> blood-stage parasites are committed to developing into sexual-stage gametocytes [<xref rid="B12-vaccines-12-00484" ref-type="bibr">12</xref>], the only form that can survive in the mosquito. In the blood bolus, male and female gametocytes are rapidly activated into gametes. One male gametocyte generates eight microgametes after three rounds of DNA replication. Microgametes actively move in search of activated female macrogametes for fertilization and the formation of zygotes. Zygotes differentiate into motile ookinetes that move in the blood bolus and invade the mosquito midgut to form oocysts, lodged between the midgut epithelium and the basal lamina. Each oocyst generates thousands of sporozoites that, when released, invade the mosquito salivary glands from where they are transmitted to a new human host. Out of thousands of ingested gametocytes, only a few oocysts form [<xref rid="B11-vaccines-12-00484" ref-type="bibr">11</xref>], defining a strong bottleneck. Malaria vaccines that target mosquito-stage parasite development are called transmission-blocking vaccines (TBV).</p><p>Transition through bottlenecks involves specific cell-cell recognition steps. For liver infection, sporozoites specifically interact with the phagocytic Kupffer cells that line the sinusoids to exit the circulation and then specifically infect hepatocytes and no other cell type. In the mosquito, fertilization requires specific recognition between male and female gametes and ookinete traversal involves its recognition of mosquito midgut epithelium receptors. Using a phage-peptide display approach, [parasite ligand-host cell receptor] pairs involved in these parasite bottlenecks have been identified [<xref rid="B13-vaccines-12-00484" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-12-00484" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-12-00484" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-12-00484" ref-type="bibr">16</xref>]. Interestingly, many of the parasite surface ligands are conserved moonlighting proteins that have acquired separate ligand functions. This review provides an overview of these <italic toggle="yes">P. falciparum</italic> parasite ligands and evaluates their potential for the development of novel malaria vaccine antigens.</p></sec><sec id="sec2-vaccines-12-00484"><title>2. Pre-Erythrocytic <italic toggle="yes">Plasmodium</italic> Ligands</title><p><italic toggle="yes">Plasmodium</italic> sporozoites interact with Kupffer cells to leave the circulation and enter the liver parenchyma [<xref rid="B4-vaccines-12-00484" ref-type="bibr">4</xref>]. Sporozoite surface glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was identified as a ligand for Kupffer cell traversal [<xref rid="B15-vaccines-12-00484" ref-type="bibr">15</xref>]. In the liver parenchyma, sporozoites specifically infect hepatocytes using the phospholipid scramblase (PLSCR) protein as a ligand [<xref rid="B14-vaccines-12-00484" ref-type="bibr">14</xref>].</p><sec id="sec2dot1-vaccines-12-00484"><title>2.1. Sporozoite Exit from the Circulation</title><p>A phage peptide-display library that displays 12 amino acid random peptides fused to the coat protein pVIII of the M13 filamentous phage was screened against a primary rat Kupffer cell culture [<xref rid="B17-vaccines-12-00484" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-12-00484" ref-type="bibr">18</xref>]. The selected Kupffer cell-binding P39 peptide (DCAIVYAYDPCL) competitively inhibited sporozoite-Kupffer cell interaction in vitro. This suggested that the P39 peptide binds to a Kupffer cell receptor for sporozoite interaction. Far-Western blotting using the P39 peptide as a probe and mass spectrometry assays identified the Kupffer cell CD68 protein as the P39 peptide binding target. Confirming this finding, sporozoite liver infection is significantly reduced in CD68KO mice [<xref rid="B18-vaccines-12-00484" ref-type="bibr">18</xref>]. These findings suggested that P39 is a structural mimic of a sporozoite ligand for CD68 interaction. To test this hypothesis, antibodies against the P39 peptide were generated. These antibodies were bound to a ~40 kDa sporozoite surface molecule [<xref rid="B15-vaccines-12-00484" ref-type="bibr">15</xref>]. Immunoprecipitation and mass spectrometry assays identified the ~40 kDa sporozoite surface protein <italic toggle="yes">Plasmodium</italic> GAPDH as a ligand for CD68 interaction. Follow-up studies found that anti-P39 antibodies bind to two epitopes in the GAPDH C-terminal end and antibodies against these epitopes inhibited sporozoite liver infection in vivo [<xref rid="B19-vaccines-12-00484" ref-type="bibr">19</xref>]. </p><p>The canonical role of GAPDH is to facilitate the conversion of glyceraldehyde-3-phosphate into 1&#8211;3 di-phosphoglycerate during glycolysis [<xref rid="B20-vaccines-12-00484" ref-type="bibr">20</xref>]. Although GAPDH acts as a quintessential housekeeping protein for cell energy production across many species, research identified GAPDH as a moonlighting protein whose function extends well beyond its traditional role in glycolysis. GAPDH is involved in DNA repair, gene expression control, cell signaling, and interaction with other molecules such as RNA and protein. Furthermore, diverse infectious microbes expose GAPDH onto their surface and utilize it for attachment to host cell protein, extracellular matrix degradation, modification of cell signaling, immune evasion, and virulence factor [<xref rid="B20-vaccines-12-00484" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-12-00484" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-12-00484" ref-type="bibr">22</xref>]. These properties have spotlighted GAPDH as a vaccine target for bacterial and parasitic diseases. For instance, immunization with recombinant GAPDH of <italic toggle="yes">Erysipelothrix rhusiopathiae</italic>, the causative agent of animal erysipelas and human erysipeloid, elicited sterile protection in a mouse model [<xref rid="B23-vaccines-12-00484" ref-type="bibr">23</xref>]. Immunization with recombinant GAPDH of <italic toggle="yes">Streptococcus dysgalactiae</italic>, a bacterial pathogen causing intramammary infections in dairy bovines, improved the survival rates and decreased the bacterial burdens in the mammary glands in immunized mice [<xref rid="B24-vaccines-12-00484" ref-type="bibr">24</xref>]. Conserved GAPDH peptides among multiple pathogens have been explored for a universal vaccine antigen that targets <italic toggle="yes">Listeria monocytogenes</italic>, <italic toggle="yes">Mycobacterium marinum</italic>, and <italic toggle="yes">Streptococcus pneumoniae</italic> [<xref rid="B25-vaccines-12-00484" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-12-00484" ref-type="bibr">26</xref>]. On the other hand, predicted GAPDH B-cell epitopes and pyruvate dehydrogenase E1 subunit alpha in <italic toggle="yes">Streptococcus iniae</italic>, a bacterial flounder pathogen, were fused for a multiple-epitope vaccine antigen, which increased survival rate in immunized animals compared to single-antigen immunized animals [<xref rid="B27-vaccines-12-00484" ref-type="bibr">27</xref>]. Multiple-epitope vaccines using <italic toggle="yes">Schistosoma mansoni</italic> GAPDH and Sm10-DLC (a 10-kDa dynein light chain protein) peptides showed protection in a mouse model [<xref rid="B28-vaccines-12-00484" ref-type="bibr">28</xref>]. The challenge, however, lies in distinguishing between the host and pathogen GAPDH proteins to avoid potential autoimmune reactions, necessitating the identification of protective epitopes unique to the pathogen protein. </p><p>Four major requirements of potential vaccine antigens are: (1) to contain the sequence located within the ligand region that interacts with the target receptor, (2) to have low genetic polymorphism, (3) not to be too similar to the host homologs, and (4) to have immunogenicity that generates protective efficacy. <italic toggle="yes">GAPDH</italic> genes among human-infecting <italic toggle="yes">Plasmodium</italic> species are well-conserved at the level of 87% identity [<xref rid="B15-vaccines-12-00484" ref-type="bibr">15</xref>]. However, <italic toggle="yes">Plasmodium</italic> GAPDH identity, with its human counterpart, is lower, at the level of 64% identity (<xref rid="vaccines-12-00484-t001" ref-type="table">Table 1</xref>). Genetic polymorphism is low, with only one non-synonymous single nucleotide polymorphism (NS-SNP) having been identified out of 275 <italic toggle="yes">P. falciparum</italic> strains (<xref rid="vaccines-12-00484-t001" ref-type="table">Table 1</xref>). There are nine parasite-specific GAPDH peptides that are well-conserved among <italic toggle="yes">Plasmodium</italic> species and divergent from mammalian orthologs [<xref rid="B15-vaccines-12-00484" ref-type="bibr">15</xref>]. Interestingly, two <italic toggle="yes">Plasmodium</italic>-specific GAPDH peptides were identified as epitopes for Kupffer cell interaction [<xref rid="B19-vaccines-12-00484" ref-type="bibr">19</xref>]. Antibodies against these epitope peptides do not cross-react with the mammalian GAPDH. Indeed, these antibodies significantly inhibited sporozoite liver infection in mice. One of these peptides, G6-1-20, overlaps with a parasite-specific B-cell epitope (GAPDH 283&#8211;292, see <xref rid="vaccines-12-00484-t002" ref-type="table">Table 2</xref>). Therefore, parasite-specific GAPDH epitope peptides are candidates for novel malaria vaccine antigens. Since these epitopes are small (20 amino acids), they could be fused to existing malaria vaccine antigens for additive or synergistic protective efficacy [<xref rid="B29-vaccines-12-00484" ref-type="bibr">29</xref>]. </p></sec><sec id="sec2dot2-vaccines-12-00484"><title>2.2. Hepatocyte Infection</title><p>The same phage-peptide display library was used to screen for peptides that bind to freshly isolated mouse hepatocytes [<xref rid="B14-vaccines-12-00484" ref-type="bibr">14</xref>]. Out of five candidates, the HP1 peptide (NCTSNDIWESCT) was the strongest hepatocyte-binding peptide, and this peptide competitively inhibited sporozoite-hepatocyte interaction in vitro [<xref rid="B14-vaccines-12-00484" ref-type="bibr">14</xref>]. The basic hypothesis was that HP1 is a structural mimic of a sporozoite ligand for hepatocyte interaction and competes with the sporozoite for binding to the hepatocyte receptor. Supporting this hypothesis, anti-HP1 antibodies recognized molecules on the surface of unpermeabilized <italic toggle="yes">P. berghei</italic> and <italic toggle="yes">P. falciparum</italic> sporozoites. On Western blots of <italic toggle="yes">P. berghei</italic> sporozoite lysates, anti-HP1 antibodies bound to a ~50 kDa sporozoite protein and mass spectrometry identified 6 candidate sporozoite proteins of this size range. All 6 candidates were expressed as recombinant proteins, of which anti-HP1 antibodies recognized only PbPLSCR. In parallel, a hepatocyte membrane protein for HP1 peptide binding was identified as Carbamoyl-phosphate synthase 1 (Cps1). Interaction of PbPLSCR with Cps1 was confirmed with pull-down and ELISA assays, leading to the identification of <italic toggle="yes">Plasmodium</italic> PLSCR and hepatocyte Cps1 as sporozoite ligand and hepatocyte receptor proteins, respectively.</p><p>PLSCR is a type II membrane protein, whose N&#8217;-terminal region is predicted to face the cytosolic space, with the C-terminal end to be embedded in the membrane. PLSCR catalyzes the scrambling of asymmetrically polarized plasma membrane phospholipid components in a Ca<sup>2+</sup>-dependent and ATP-independent manner [<xref rid="B30-vaccines-12-00484" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-12-00484" ref-type="bibr">31</xref>]. Mammalian cell membranes are enriched for sphingomyelin and phosphatidylcholine in the outer leaflet and enriched for phosphatidylserine (PS), phosphatidylethanolamine, and phosphatidylinositol in the inner leaflet. PLSCRs activate the externalization of PS, which activates blood coagulation and apoptosis. There are three phospholipid scrambling enzyme families: the PLSCR family, the TMEM16 family, and the XKR family [<xref rid="B30-vaccines-12-00484" ref-type="bibr">30</xref>]. Only the PLSCR family has structural similarity with Tubby-like proteins which possess a 12-stranded beta barrel surrounding a central alpha helix. <italic toggle="yes">Plasmodium</italic> PLSCR has the conserved structure of the PLSCR family [<xref rid="B32-vaccines-12-00484" ref-type="bibr">32</xref>] and its scramblase activity was confirmed; however, PfPLSCR is dispensable for blood-stage growth [<xref rid="B33-vaccines-12-00484" ref-type="bibr">33</xref>]. Apart from these canonical activities, PLSCR has additional functions as a moonlighting protein [<xref rid="B34-vaccines-12-00484" ref-type="bibr">34</xref>]. PLSCR can be secreted into the extracellular matrix (ECM) or enter the nucleus. In the cytosolic space, PLSCRs interact with other proteins involved in cell death, autophagy, inflammation, molecular trafficking, and gene regulation. In the extracellular space or endosomal compartment, PLSCRs interact with viruses or other cellular receptor molecules for internalization. Some enveloped viruses utilize canonical scramblase function to induce PS exposure on the host cell membrane, which serves as the viral envelope that induces apoptotic mimicry that facilitates viral entry through host cell phagocytosis. On the other hand, human PLSCR1 targets SARS-CoV-2-containing vesicles and inhibits virus entry and membrane fusion by the spike protein through its ectodomain (&#946;-barrels and C-terminal helix), which has no direct correlation with scramblase activity [<xref rid="B35-vaccines-12-00484" ref-type="bibr">35</xref>].</p><p>PfPLSCR has the potential for a PEV antigen since it is highly expressed on the sporozoite surface [<xref rid="B14-vaccines-12-00484" ref-type="bibr">14</xref>,<xref rid="B29-vaccines-12-00484" ref-type="bibr">29</xref>,<xref rid="B33-vaccines-12-00484" ref-type="bibr">33</xref>,<xref rid="B36-vaccines-12-00484" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-12-00484" ref-type="bibr">37</xref>]. As the human PLSCR1 ectodomain (which is exposed at the extracellular surface) acts as a moonlighting protein for inhibition of SARS-CoV-2 entry, the PfPLSCR ectodomain (which is exposed at the parasite surface and has no correlation with scramblase activity) is expected to act as a ligand for hepatocyte interaction. Therefore, only one predicted <italic toggle="yes">Plasmodium</italic>-specific B-cell epitope (MGFKLDFN, <xref rid="vaccines-12-00484-t002" ref-type="table">Table 2</xref>) in the ectodomain is expected to generate protective antibodies. The other epitope peptides are expected to be located in the cytosolic compartment. It is expected that the ligand epitope in the ectodomain may contribute for protective immunity when used as an antigen. Except for the <italic toggle="yes">Plasmodium</italic> sporozoite, PLSCR has never been investigated as a ligand of infectious microbes or a vaccine candidate. <italic toggle="yes">Plasmodium</italic> has one PLSCR gene, and PLSCR genes among <italic toggle="yes">Plasmodium</italic> species are well-conserved (~75% identity) [<xref rid="B14-vaccines-12-00484" ref-type="bibr">14</xref>]; however, the human genome has 5 PLSCR genes and 10 isoforms (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://uniprot.org">https://uniprot.org</uri> (accessed on 28 March 2024)), of which maximum identity reaches 21% when compared with human PLSCR3. Moreover, only two non-synonymous PfPLSCR SNPs have been reported out of 301 sequenced strains (<xref rid="vaccines-12-00484-t001" ref-type="table">Table 1</xref>). Divergent sequence identity from mammalian host proteins and low polymorphism in the field favor the potential use of PfPLSCR as an additional malaria vaccine antigen. Indeed, antibodies against PbPLSCR inhibited both <italic toggle="yes">P. berghei</italic> in vivo and <italic toggle="yes">P. falciparum</italic> sporozoite-hepatocyte interaction in vitro [<xref rid="B14-vaccines-12-00484" ref-type="bibr">14</xref>]. Genetic polymorphism of a vaccine antigen can dampen enthusiasm for its general application. PfCSP, the most prominent malaria vaccine antigen, has 48 NS-SNPs out of 310 sequenced strains and 14% of mutant alleles have frequencies over 30%. On the other hand, two SNPs in PfPLSCR were identified in the cytosolic N&#8217;-terminal region with 1% frequency (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://plasmodb.org">https://plasmodb.org</uri> (accessed on 28 March 2024)).</p></sec></sec><sec id="sec3-vaccines-12-00484"><title>3. <italic toggle="yes">Plasmodium</italic> Ligands in the Mosquito</title><p>The first specific parasite interaction in the mosquito midgut occurs between male and female gametes at fertilization. Female gamete heat-shock protein 90 (HSP90) was identified as a ligand for fertilization [<xref rid="B16-vaccines-12-00484" ref-type="bibr">16</xref>]. The zygote then develops into an ookinete that moves to the mosquito midgut epithelium. Ookinetes traverse the mosquito midgut using surface enolase as a ligand [<xref rid="B13-vaccines-12-00484" ref-type="bibr">13</xref>] and then differentiate into oocysts that produce thousands of sporozoites. </p><sec id="sec3dot1-vaccines-12-00484"><title>3.1. Fertilization</title><p>Purified male <italic toggle="yes">P. berghei</italic> gametocytes were incubated with a phage-peptide display library for selecting male gamete-binding peptides. The MG1 peptide (SFRSRLQPYSCA) was selected and it competitively inhibited <italic toggle="yes">P. berghei</italic> and <italic toggle="yes">P. falciparum</italic> fertilization, both in vitro and in the mosquito midgut [<xref rid="B16-vaccines-12-00484" ref-type="bibr">16</xref>]. The hypothesis that MG1 peptide is a structural mimic of a female gamete protein for fertilization was confirmed with assays using anti-MG1 antibodies. Anti-MG1 antibodies bound to the female gamete surface and recognized a ~110 kDa female gamete membrane protein. Mass spectrometry assay identified three candidate proteins in this size range that were expressed as recombinant proteins. Anti-MG1 antibodies recognized <italic toggle="yes">Plasmodium</italic> heat-shock protein 90 (HSP90) only. Immuno-fluorescence assays confirmed surface exposure of HSP90 on <italic toggle="yes">P. berghei</italic> and <italic toggle="yes">P. falciparum</italic> female gametes. Moreover, anti-HSP90 antibodies inhibited gamete fertilization in the mosquito midgut confirming that <italic toggle="yes">Plasmodium</italic> female gamete HSP90 as a fertilization ligand. </p><p>HSP90 is a well-known molecular chaperone that plays crucial roles in various cellular processes, including signal transduction, protein folding, and response to stress conditions. Canonical roles of HSP90 include facilitating protein folding, stabilization, and activation of a wide range of client proteins [<xref rid="B38-vaccines-12-00484" ref-type="bibr">38</xref>]. HSP90 operates as a homodimer whose conformation is regulated by ATP binding to its N&#8217;-terminal ATPase domain. The binding of various co-chaperones can modulate its activity. HSP90 function is not limited to the intracellular environment; extracellular HSP90 also plays a role in immune responses by interacting with surface receptors on immune cells, thereby modulating cellular functions such as cytokine secretion, cell maturation, and antigen presentation. HSP90 has been explored as an adjuvant since it activates and modulates professional antigen-presenting cells to induce robust immune responses [<xref rid="B39-vaccines-12-00484" ref-type="bibr">39</xref>]. As is the case for <italic toggle="yes">Plasmodium</italic>, mammalian oocyte surface HSP90s are important for fertilization as well [<xref rid="B40-vaccines-12-00484" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-12-00484" ref-type="bibr">41</xref>]. Surface HSP90 exposure on diverse infectious microorganisms has been reported, which suggests HSP90 may be a vaccine candidate. Immunoblotting assays using convalescent sera from <italic toggle="yes">Streptococcus oralis</italic>-infected patients detected two immunodominant antigens. An 85 kDa protein was identified as HSP90 and antibodies against HSP90 protected immunized animals [<xref rid="B42-vaccines-12-00484" ref-type="bibr">42</xref>]. HSP90 of the oriental liver fluke, <italic toggle="yes">Clonorchis sinensis</italic>, was assessed for T-cell activation and antibody production [<xref rid="B43-vaccines-12-00484" ref-type="bibr">43</xref>]. Antisera against human fungal disease <italic toggle="yes">Aspergillus fumigatus</italic> identified enolase and HSP90 as vaccine candidates [<xref rid="B44-vaccines-12-00484" ref-type="bibr">44</xref>]. Proteome analysis using antisera against <italic toggle="yes">Borrelia burgdorferi</italic>, a causative agent of Lyme disease, identified HSP90 as an immunodominant antigen [<xref rid="B45-vaccines-12-00484" ref-type="bibr">45</xref>]. Two HSP90 epitopes of <italic toggle="yes">Candida albicans</italic>, an opportunistic pathogenic yeast, have been identified and applied as vaccine antigens for protective immunity [<xref rid="B46-vaccines-12-00484" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-12-00484" ref-type="bibr">47</xref>].</p><p><italic toggle="yes">P. falciparum</italic> has one HSP90 gene and humans have two genes and three isoforms, of which the maximum <italic toggle="yes">Plasmodium</italic>-human identity is 75% (HsHSP90B, <xref rid="vaccines-12-00484-t001" ref-type="table">Table 1</xref>). Seven non-synonymous SNPs were identified out of 301 sequenced <italic toggle="yes">P. falciparum</italic> strains, of which 6 NS-SNPs were found in the predicted B-cell epitope PfHSP90_211&#8211;340 (<xref rid="vaccines-12-00484-t002" ref-type="table">Table 2</xref>). <italic toggle="yes">Plasmodium</italic> HSP90 is recognized as a potential vaccine candidate since it is exposed on the parasite surface during diverse stages, even on the infected RBC surface, which is important for fertilization and essential for blood-stage parasite growth [<xref rid="B40-vaccines-12-00484" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-12-00484" ref-type="bibr">41</xref>,<xref rid="B48-vaccines-12-00484" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-12-00484" ref-type="bibr">49</xref>,<xref rid="B50-vaccines-12-00484" ref-type="bibr">50</xref>,<xref rid="B51-vaccines-12-00484" ref-type="bibr">51</xref>,<xref rid="B52-vaccines-12-00484" ref-type="bibr">52</xref>]. Antibodies against <italic toggle="yes">P. berghei</italic> HSP90 inhibited parasite fertilization, which shows the potential of <italic toggle="yes">Plasmodium</italic> HSP90 as a TBV antigen [<xref rid="B16-vaccines-12-00484" ref-type="bibr">16</xref>]. Anti-sporozoite and anti-asexual blood stage parasite activity of these antibodies is yet to be assessed. Since HSP90 acts as a chaperon molecule in diverse pathways and surface exposure of HSP90 was confirmed at multiple parasite stages [<xref rid="B48-vaccines-12-00484" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-12-00484" ref-type="bibr">49</xref>,<xref rid="B50-vaccines-12-00484" ref-type="bibr">50</xref>], the utility of anti-HSP90 antibodies may extend beyond the TBV. Despite PfHSP90&#8217;s high sequence identity with human orthologs, there are over 20 divergent peptides with an identity lower than 50%, of which four of them are predicted to be B-cell epitopes (<xref rid="vaccines-12-00484-t002" ref-type="table">Table 2</xref>). </p></sec><sec id="sec3dot2-vaccines-12-00484"><title>3.2. Traversal of the Midgut Epithelium</title><p>Screening for mosquito midgut-binding peptides using a phage-peptide display library led to the identification of the <italic toggle="yes">Plasmodium</italic> ookinete surface enolase as a ligand for mosquito midgut invasion [<xref rid="B53-vaccines-12-00484" ref-type="bibr">53</xref>]. The selected SM1 peptide (PCQRAIFQSICN) bound to the luminal side of the mosquito midgut and prevented interaction with ookinetes. This suggested that the SM1 peptide binds to a receptor on the mosquito midgut for ookinete invasion and that the SM1 peptide mimics the conformation of an ookinete ligand for midgut interaction. This hypothesis was confirmed with a series of assays using anti-SM1 antibodies. Immunofluorescence assays showed that anti-SM1 antibodies bind to both <italic toggle="yes">P. berghei</italic> and <italic toggle="yes">P. falciparum</italic> ookinete surfaces. A Western blotting assay found that the anti-SM1 antibodies bound to two, ~65 kDa and ~48 kDa, major protein bands. Mass spectrometry assay identified the 65 kDa protein as RNA helicase, which is a cytoplasmic protein, and the 48 kDa protein as enolase. Recombinant <italic toggle="yes">P. falciparum</italic> enolase was generated for the production of antibodies in rabbits. Immuno-electron microscopy confirmed the surface localization of <italic toggle="yes">P. berghei</italic> ookinete enolase. Importantly, anti-enolase antibodies inhibited <italic toggle="yes">P. berghei</italic> and <italic toggle="yes">P. falciparum</italic> ookinete midgut invasion [<xref rid="B13-vaccines-12-00484" ref-type="bibr">13</xref>]. </p><p>The main function of enolase is the catalysis of 2-phosphoglycerate to phosphoenolpyruvate, reordering the single bond between carbon atoms to form a higher energy double bond in glycolysis [<xref rid="B54-vaccines-12-00484" ref-type="bibr">54</xref>]. However, as a moonlighting protein, enolase plays an important role in diverse pathogenic microorganisms for adhering to the ECM of various organisms [<xref rid="B54-vaccines-12-00484" ref-type="bibr">54</xref>,<xref rid="B55-vaccines-12-00484" ref-type="bibr">55</xref>]. As an adherence factor, enolase interacts with host ECM and recruits mammalian plasminogen, which in turn plays a key role in the fibrinolytic system maintaining homeostasis via the creation and dissolution of fibrin clots. Plasminogen should be activated into plasmin for fibrinolysis and plasminogen binding to enolase promotes this activation, thus allowing pathogens to traverse the host ECM [<xref rid="B56-vaccines-12-00484" ref-type="bibr">56</xref>]. Plasminogen-enolase interaction plays an important role in the <italic toggle="yes">Plasmodium</italic> ookinete mosquito midgut invasion. In addition to serving as a mosquito midgut ligand, ookinete surface enolase mediates the binding of blood plasminogen via a C-terminal 6-amino acid motif (DKSLVK) that is recognized by a lysine-binding Kringle domain of the plasminogen. Confirming this role, feeding an infectious blood meal with excess soluble 6-aa peptide competitively inhibited ookinete mosquito midgut invasion by preventing plasminogen binding to ookinete surface enolase [<xref rid="B13-vaccines-12-00484" ref-type="bibr">13</xref>]. </p><p>Enolase has been investigated as a vaccine candidate to protect from diverse infectious microbes. The avian bacterial pathogen, <italic toggle="yes">Mycoplasma synoviae</italic>, uses enolase as an adherence factor. Immunization and challenge assayusing six major immunogenic antigens identified that enolase elicited the best protective efficacy in challenged chickens [<xref rid="B57-vaccines-12-00484" ref-type="bibr">57</xref>]. This trend was also seen in ticks, where it was shown that anti-enolase antibodies reduced tick attachment [<xref rid="B58-vaccines-12-00484" ref-type="bibr">58</xref>]. The bovine disease-causing bacterium <italic toggle="yes">Anaplasmasa marginale</italic> uses enolase for attachment to the host erythrocyte surface. <italic toggle="yes">A. marginale</italic> AmEno01 protein was identified as a vaccine candidate, as it exists across all groups of <italic toggle="yes">A. marginale</italic> strains with well-conserved 3D structures [<xref rid="B59-vaccines-12-00484" ref-type="bibr">59</xref>]. Bioinformatics studies of enolase in <italic toggle="yes">Trypanosoma cruzi</italic>, a causative agent of American trypanosomiasis, identified a consensus sequence of the enolase protein from 15 <italic toggle="yes">T. cruzi</italic> strains as a vaccine candidate [<xref rid="B60-vaccines-12-00484" ref-type="bibr">60</xref>]. </p><p><italic toggle="yes">Plasmodium</italic> enolase is a promising TBV antigen candidate since it is exposed on the ookinete surface for interaction with a mosquito midgut receptor and is important for the movement of ookinete in the blood bolus using the fibrinolysis pathway. Indeed, anti-enolase antibodies inhibited ookinete mosquito invasion. Interestingly, treatment of 6-aa peptide for a lysine-binding Kringle domain competitively inhibited parasite mosquito midgut invasion with similar efficacy as antibody treatment, which suggests that antibody against the 6-aa peptide can inhibit ookinete midgut invasion [<xref rid="B13-vaccines-12-00484" ref-type="bibr">13</xref>]. Due to its small size, the 6-aa peptide can be fused with an existing antigen for immunization. </p></sec></sec><sec sec-type="conclusions" id="sec4-vaccines-12-00484"><title>4. Conclusions and Perspectives</title><p>All merozoite ligands for RBC infection identified so far are parasite-specific proteins [<xref rid="B9-vaccines-12-00484" ref-type="bibr">9</xref>]. In contrast, all parasite ligands at two major population bottlenecks are moonlighting proteins acting uncoupled from their canonical roles. In terms of vaccine development, concerns are not related to their multifunctional properties, but to their conserved protein structures and sequences with host protein orthologues. One hypothesis for why infectious microorganisms use conserved moonlighting proteins as ligands is that the host will not elicit antibodies against these conserved proteins. Indeed, most of the predicted linear B-cell epitopes in the microbes and human protein orthologues overlap [<xref rid="B61-vaccines-12-00484" ref-type="bibr">61</xref>]. However, the parasite ligand epitope peptides for host cell recognition may not be located only in highly conserved regions. Two <italic toggle="yes">Plasmodium</italic> sporozoite GAPDH epitopes, G6-1-20 and G6-41-60, which are peptides for CD68 interaction, have 70% and 65% identities with host proteins and antibodies against these epitope peptides do not cross-react with the host protein [<xref rid="B19-vaccines-12-00484" ref-type="bibr">19</xref>]. Although these epitope peptides are not located in the immunodominant regions, immunization of each epitope peptide elicited enough antibodies for protective immunity. Therefore, epitope-based vaccination strategies will resolve conserved antigen issues and will enable easy fusion of multiple epitope antigens for increased protective efficacy. </p><p>A major weakness of TBVs is that transmission-blocking antibodies do not protect the immunized hosts. Thus, the addition to the TBV of an antigen that confers protective immunity to the vaccinated person is highly desirable. Optimizing an immunization regimen for two different vaccine antigens has many hurdles. The molecular size of the most advanced PEV (RTS,S/AS01E) or the most advanced TBV (P230) is large enough to generate broad-range polyclonal antibodies that can &#8216;dilute&#8217; protection efficiency by generating antibodies unrelated to protection [<xref rid="B7-vaccines-12-00484" ref-type="bibr">7</xref>,<xref rid="B62-vaccines-12-00484" ref-type="bibr">62</xref>]. Immunization with two large antigens may elicit competition and immunodominance of antibodies irrelevant to protection. The development of fusion vaccine antigens containing multiple epitopes targeting both liver infection and mosquito transmission will improve malaria vaccine strategies to prevent both infection of humans and transmission to mosquitoes. Of note, parasite ligands in the two major population bottlenecks were identified through host cell binding peptide selection. All the selected peptides were identified as structural mimics of parasite ligands. Immunization with these peptides elicited protective antibodies, which strongly implies the feasibility of using these peptides, instead of parasite-host antigens, as vaccine antigens. </p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, writing&#8212;original draft preparation, review, and editing: S.K., M.P.P., A.D.P. and S.-J.C. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-00484"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kebaier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Voza</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vanderberg</surname><given-names>J.</given-names></name></person-group><article-title>Kinetics of Mosquito-Injected <italic toggle="yes">Plasmodium</italic> Sporozoites in Mice: Fewer Sporozoites Are Injected into Sporozoite-Immunized Mice</article-title><source>PLoS Pathog.</source><year>2009</year><volume>5</volume><elocation-id>e1000399</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000399</pub-id><pub-id pub-id-type="pmid">19390607</pub-id><pub-id pub-id-type="pmcid">PMC2667259</pub-id></element-citation></ref><ref id="B2-vaccines-12-00484"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Pukrittayakamee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hien</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Faiz</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mokuolu</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Dondorp</surname><given-names>A.M.</given-names></name></person-group><article-title>Malaria</article-title><source>Lancet</source><year>2014</year><volume>383</volume><fpage>723</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)60024-0</pub-id><pub-id pub-id-type="pmid">23953767</pub-id></element-citation></ref><ref id="B3-vaccines-12-00484"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pradel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Garapaty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Frevert</surname><given-names>U.</given-names></name></person-group><article-title>Kupffer and Stellate Cell Proteoglycans Mediate Malaria Sporozoite Targeting to the Liver</article-title><source>Comp. Hepatol.</source><year>2004</year><volume>3</volume><issue>(Suppl. S1)</issue><fpage>S47</fpage><pub-id pub-id-type="doi">10.1186/1476-5926-2-S1-S47</pub-id><pub-id pub-id-type="pmid">14960199</pub-id><pub-id pub-id-type="pmcid">PMC2410262</pub-id></element-citation></ref><ref id="B4-vaccines-12-00484"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frevert</surname><given-names>U.</given-names></name><name name-style="western"><surname>Engelmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zougbede</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stange</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Matuschewski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liebes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yee</surname><given-names>H.</given-names></name></person-group><article-title>Intravital Observation of <italic toggle="yes">Plasmodium</italic> Berghei Sporozoite Infection of the Liver</article-title><source>PLoS Biol.</source><year>2005</year><volume>3</volume><elocation-id>e192</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.0030192</pub-id><pub-id pub-id-type="pmid">15901208</pub-id><pub-id pub-id-type="pmcid">PMC1135295</pub-id></element-citation></ref><ref id="B5-vaccines-12-00484"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tavares</surname><given-names>J.</given-names></name><name name-style="western"><surname>Formaglio</surname><given-names>P.</given-names></name><name name-style="western"><surname>Thiberge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mordelet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Van Rooijen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Medvinsky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Menard</surname><given-names>R.</given-names></name><name name-style="western"><surname>Amino</surname><given-names>R.</given-names></name></person-group><article-title>Role of Host Cell Traversal by the Malaria Sporozoite during Liver Infection</article-title><source>J. Exp. Med.</source><year>2013</year><volume>210</volume><fpage>905</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1084/jem.20121130</pub-id><pub-id pub-id-type="pmid">23610126</pub-id><pub-id pub-id-type="pmcid">PMC3646492</pub-id></element-citation></ref><ref id="B6-vaccines-12-00484"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sturm</surname><given-names>A.</given-names></name><name name-style="western"><surname>Amino</surname><given-names>R.</given-names></name><name name-style="western"><surname>van de Sand</surname><given-names>C.</given-names></name><name name-style="western"><surname>Regen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Retzlaff</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rennenberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pollok</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Menard</surname><given-names>R.</given-names></name><name name-style="western"><surname>Heussler</surname><given-names>V.T.</given-names></name></person-group><article-title>Manipulation of Host Hepatocytes by the Malaria Parasite for Delivery into Liver Sinusoids</article-title><source>Science</source><year>2006</year><volume>313</volume><fpage>1287</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1126/science.1129720</pub-id><pub-id pub-id-type="pmid">16888102</pub-id></element-citation></ref><ref id="B7-vaccines-12-00484"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duffy</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Gorres</surname><given-names>J.P.</given-names></name></person-group><article-title>Malaria Vaccines since 2000: Progress, Priorities, Products</article-title><source>NPJ Vaccines</source><year>2020</year><volume>5</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1038/s41541-020-0196-3</pub-id><pub-id pub-id-type="pmid">32566259</pub-id><pub-id pub-id-type="pmcid">PMC7283239</pub-id></element-citation></ref><ref id="B8-vaccines-12-00484"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsoumani</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Voyiatzaki</surname><given-names>C.</given-names></name><name name-style="western"><surname>Efstathiou</surname><given-names>A.</given-names></name></person-group><article-title>Malaria Vaccines: From the Past Towards the mRNA Vaccine Era</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1452</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11091452</pub-id><pub-id pub-id-type="pmid">37766129</pub-id><pub-id pub-id-type="pmcid">PMC10536368</pub-id></element-citation></ref><ref id="B9-vaccines-12-00484"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Gilson</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Taechalertpaisarn</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tham</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>N.W.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Fowkes</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Barlow</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Rayner</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>G.J.</given-names></name><etal/></person-group><article-title>Revealing the Sequence and Resulting Cellular Morphology of Receptor-Ligand Interactions during <italic toggle="yes">Plasmodium falciparum</italic> Invasion of Erythrocytes</article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><elocation-id>e1004670</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004670</pub-id><pub-id pub-id-type="pmid">25723550</pub-id><pub-id pub-id-type="pmcid">PMC4344246</pub-id></element-citation></ref><ref id="B10-vaccines-12-00484"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duffy</surname><given-names>P.E.</given-names></name></person-group><article-title>Transmission-Blocking Vaccines: Harnessing Herd Immunity for Malaria Elimination</article-title><source>Expert Rev. Vaccines</source><year>2021</year><volume>20</volume><fpage>185</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1080/14760584.2021.1878028</pub-id><pub-id pub-id-type="pmid">33478283</pub-id><pub-id pub-id-type="pmcid">PMC11127254</pub-id></element-citation></ref><ref id="B11-vaccines-12-00484"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Vega-Rodr&#237;guez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jacobs-Lorena</surname><given-names>M.</given-names></name></person-group><article-title>The <italic toggle="yes">Plasmodium</italic> Bottleneck: Malaria Parasite Losses in the Mosquito Vector</article-title><source>Mem. Inst. Oswaldo Cruz</source><year>2014</year><volume>109</volume><fpage>644</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1590/0074-0276130597</pub-id><pub-id pub-id-type="pmid">25185005</pub-id><pub-id pub-id-type="pmcid">PMC4156458</pub-id></element-citation></ref><ref id="B12-vaccines-12-00484"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tadesse</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Meerstein-Kessel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Goncalves</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Drakeley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ranford-Cartwright</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bousema</surname><given-names>T.</given-names></name></person-group><article-title>Gametocyte Sex Ratio: The Key to Understanding <italic toggle="yes">Plasmodium falciparum</italic> Transmission?</article-title><source>Trends Parasitol.</source><year>2019</year><volume>35</volume><fpage>226</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2018.12.001</pub-id><pub-id pub-id-type="pmid">30594415</pub-id><pub-id pub-id-type="pmcid">PMC6396025</pub-id></element-citation></ref><ref id="B13-vaccines-12-00484"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Coppens</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gardsvoll</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ploug</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jacobs-Lorena</surname><given-names>M.</given-names></name></person-group><article-title><italic toggle="yes">Plasmodium</italic> Ookinetes Coopt Mammalian Plasminogen to Invade the Mosquito Midgut</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>17153</fpage><lpage>17158</lpage><pub-id pub-id-type="doi">10.1073/pnas.1103657108</pub-id><pub-id pub-id-type="pmid">21949403</pub-id><pub-id pub-id-type="pmcid">PMC3193258</pub-id></element-citation></ref><ref id="B14-vaccines-12-00484"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cha</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Na</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Jacobs-Lorena</surname><given-names>M.</given-names></name></person-group><article-title><italic toggle="yes">Plasmodium</italic> Sporozoite Phospholipid Scramblase Interacts with Mammalian Carbamoyl-Phosphate Synthetase 1 to Infect Hepatocytes</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>6773</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-27109-7</pub-id><pub-id pub-id-type="pmid">34799567</pub-id><pub-id pub-id-type="pmcid">PMC8604956</pub-id></element-citation></ref><ref id="B15-vaccines-12-00484"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cha</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jacobs-Lorena</surname><given-names>M.</given-names></name></person-group><article-title>Identification of GAPDH on the Surface of <italic toggle="yes">Plasmodium</italic> Sporozoites as a New Candidate for Targeting Malaria Liver Invasion</article-title><source>J. Exp. Med.</source><year>2016</year><volume>213</volume><fpage>2099</fpage><lpage>2112</lpage><pub-id pub-id-type="doi">10.1084/jem.20160059</pub-id><pub-id pub-id-type="pmid">27551151</pub-id><pub-id pub-id-type="pmcid">PMC5030802</pub-id></element-citation></ref><ref id="B16-vaccines-12-00484"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cha</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Vega-Rodriguez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kudyba</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Hanner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jacobs-Lorena</surname><given-names>M.</given-names></name></person-group><article-title><italic toggle="yes">Plasmodium</italic> Female Gamete Surface Hsp90 Is a Key Determinant for Fertilization</article-title><source>mBio</source><year>2023</year><volume>15</volume><elocation-id>e0314223</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.03142-23</pub-id><pub-id pub-id-type="pmid">38131664</pub-id><pub-id pub-id-type="pmcid">PMC10865824</pub-id></element-citation></ref><ref id="B17-vaccines-12-00484"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonnycastle</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Mehroke</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Rashed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>J.K.</given-names></name></person-group><article-title>Probing the Basis of Antibody Reactivity with a Panel of Constrained Peptide Libraries Displayed by Filamentous Phage</article-title><source>J. Mol. Biol.</source><year>1996</year><volume>258</volume><fpage>747</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1996.0284</pub-id><pub-id pub-id-type="pmid">8637007</pub-id></element-citation></ref><ref id="B18-vaccines-12-00484"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cha</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schindler</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>van Rooijen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stins</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jacobs-Lorena</surname><given-names>M.</given-names></name></person-group><article-title>CD68 Acts as a Major Gateway for Malaria Sporozoite Liver Infection</article-title><source>J. Exp. Med.</source><year>2015</year><volume>212</volume><fpage>1391</fpage><lpage>1403</lpage><pub-id pub-id-type="doi">10.1084/jem.20110575</pub-id><pub-id pub-id-type="pmid">26216124</pub-id><pub-id pub-id-type="pmcid">PMC4548058</pub-id></element-citation></ref><ref id="B19-vaccines-12-00484"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cha</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>McLean</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Jacobs-Lorena</surname><given-names>M.</given-names></name></person-group><article-title>Identification of <italic toggle="yes">Plasmodium</italic> GAPDH Epitopes for Generation of Antibodies That Inhibit Malaria Infection</article-title><source>Life Sci. Alliance</source><year>2018</year><volume>1</volume><fpage>e201800111</fpage><pub-id pub-id-type="doi">10.26508/lsa.201800111</pub-id><pub-id pub-id-type="pmid">30456380</pub-id><pub-id pub-id-type="pmcid">PMC6238388</pub-id></element-citation></ref><ref id="B20-vaccines-12-00484"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez-Casal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>A.A.</given-names></name></person-group><article-title>Glyceradehyde-3-Phosphate Dehydrogenase as a Suitable Vaccine Candidate for Protection against Bacterial and Parasitic Diseases</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>1012</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.11.072</pub-id><pub-id pub-id-type="pmid">26686572</pub-id></element-citation></ref><ref id="B21-vaccines-12-00484"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kopeckova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pavkova</surname><given-names>I.</given-names></name><name name-style="western"><surname>Stulik</surname><given-names>J.</given-names></name></person-group><article-title>Diverse Localization and Protein Binding Abilities of Glyceraldehyde-3-Phosphate Dehydrogenase in Pathogenic Bacteria: The Key to Its Multifunctionality?</article-title><source>Front. Cell Infect. Microbiol.</source><year>2020</year><volume>10</volume><elocation-id>89</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.00089</pub-id><pub-id pub-id-type="pmid">32195198</pub-id><pub-id pub-id-type="pmcid">PMC7062713</pub-id></element-citation></ref><ref id="B22-vaccines-12-00484"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Hijacking of Host Plasminogen by <italic toggle="yes">Mesomycoplasma</italic> (<italic toggle="yes">Mycoplasma</italic>) <italic toggle="yes">hyopneumoniae</italic> via GAPDH: An Important Virulence Mechanism to Promote Adhesion and Extracellular Matrix Degradation</article-title><source>Microbiol. Spectr.</source><year>2023</year><volume>11</volume><elocation-id>e0021823</elocation-id><pub-id pub-id-type="doi">10.1128/spectrum.00218-23</pub-id><pub-id pub-id-type="pmid">37199643</pub-id><pub-id pub-id-type="pmcid">PMC10269845</pub-id></element-citation></ref><ref id="B23-vaccines-12-00484"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of the Protective Efficacy of Four Newly Identified Surface Proteins of <italic toggle="yes">Erysipelothrix rhusiopathiae</italic></article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>8079</fpage><lpage>8083</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.10.071</pub-id><pub-id pub-id-type="pmid">30446176</pub-id></element-citation></ref><ref id="B24-vaccines-12-00484"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Subcutaneous <italic toggle="yes">Streptococcus dysgalactiae</italic> Gapdh Vaccine in Mice Induces a Proficient Innate Immune Response</article-title><source>J. Vet. Sci.</source><year>2023</year><volume>24</volume><fpage>e72</fpage><pub-id pub-id-type="doi">10.4142/jvs.23103</pub-id><pub-id pub-id-type="pmid">38031651</pub-id><pub-id pub-id-type="pmcid">PMC10556295</pub-id></element-citation></ref><ref id="B25-vaccines-12-00484"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvarez-Dominguez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Salcines-Cuevas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Teran-Navarro</surname><given-names>H.</given-names></name><name name-style="western"><surname>Calderon-Gonzalez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tobes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>I.</given-names></name><name name-style="western"><surname>Grijalvo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paradela</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seoane</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sangari</surname><given-names>F.J.</given-names></name><etal/></person-group><article-title>Epitopes for Multivalent Vaccines against <italic toggle="yes">Listeria</italic>, <italic toggle="yes">Mycobacterium</italic> and <italic toggle="yes">Streptococcus</italic> spp: A Novel Role for Glyceraldehyde-3-Phosphate Dehydrogenase</article-title><source>Front. Cell Infect. Microbiol.</source><year>2020</year><volume>10</volume><elocation-id>573348</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.573348</pub-id><pub-id pub-id-type="pmid">33194812</pub-id><pub-id pub-id-type="pmcid">PMC7657268</pub-id></element-citation></ref><ref id="B26-vaccines-12-00484"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salcines-Cuevas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Teran-Navarro</surname><given-names>H.</given-names></name><name name-style="western"><surname>Calderon-Gonzalez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Torres-Rodriguez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tobes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fresno</surname><given-names>M.</given-names></name><name name-style="western"><surname>Calvo-Montes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Molino-Bernal</surname><given-names>I.</given-names></name><name name-style="western"><surname>Yanez-Diaz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alvarez-Dominguez</surname><given-names>C.</given-names></name></person-group><article-title>Glyceraldehyde-3-Phosphate Dehydrogenase Common Peptides of <italic toggle="yes">Listeria monocytogenes</italic>, <italic toggle="yes">Mycobacterium marinum</italic> and <italic toggle="yes">Streptococcus pneumoniae</italic> as Universal Vaccines</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>269</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9030269</pub-id><pub-id pub-id-type="pmid">33802959</pub-id><pub-id pub-id-type="pmcid">PMC8002646</pub-id></element-citation></ref><ref id="B27-vaccines-12-00484"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>W.</given-names></name></person-group><article-title>Development and Evaluation of Recombinant B-Cell Multi-Epitopes of PDHA1 and GAPDH as Subunit Vaccines against <italic toggle="yes">Streptococcus iniae</italic> Infection in Flounder (<italic toggle="yes">Paralichthys olivaceus</italic>)</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>624</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11030624</pub-id><pub-id pub-id-type="pmid">36992208</pub-id><pub-id pub-id-type="pmcid">PMC10051852</pub-id></element-citation></ref><ref id="B28-vaccines-12-00484"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Argiro</surname><given-names>L.</given-names></name><name name-style="western"><surname>Henri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dessein</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kouriba</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dessein</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Bourgois</surname><given-names>A.</given-names></name></person-group><article-title>Induction of a Protection against <italic toggle="yes">S. mansoni</italic> with a Map Containing Epitopes of Sm37-GAPDH and Sm10-DLC. Effect of Coadsorption with GM-CSF on Alum</article-title><source>Vaccine</source><year>2000</year><volume>18</volume><fpage>2033</fpage><lpage>2038</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(99)00523-X</pub-id><pub-id pub-id-type="pmid">10706966</pub-id></element-citation></ref><ref id="B29-vaccines-12-00484"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez-Diaz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yerbanga</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Lefevre</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cohuet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Ouedraogo</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Corces</surname><given-names>V.G.</given-names></name></person-group><article-title>Epigenetic Regulation of <italic toggle="yes">Plasmodium falciparum</italic> Clonally Variant Gene Expression During Development in Anopheles Gambiae</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>40655</fpage><pub-id pub-id-type="doi">10.1038/srep40655</pub-id><pub-id pub-id-type="pmid">28091569</pub-id><pub-id pub-id-type="pmcid">PMC5238449</pub-id></element-citation></ref><ref id="B30-vaccines-12-00484"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kodigepalli</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Bowers</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nanjundan</surname><given-names>M.</given-names></name></person-group><article-title>Roles and Regulation of Phospholipid Scramblases</article-title><source>FEBS Lett.</source><year>2015</year><volume>589</volume><fpage>3</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2014.11.036</pub-id><pub-id pub-id-type="pmid">25479087</pub-id></element-citation></ref><ref id="B31-vaccines-12-00484"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rayala</surname><given-names>S.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Sivagnanam</surname><given-names>U.</given-names></name><name name-style="western"><surname>Gummadi</surname><given-names>S.N.</given-names></name></person-group><article-title>N-Terminal Proline-Rich Domain Is Required for Scrambling Activity of Human Phospholipid Scramblases</article-title><source>J. Biol. Chem.</source><year>2014</year><volume>289</volume><fpage>13206</fpage><lpage>13218</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.522953</pub-id><pub-id pub-id-type="pmid">24648509</pub-id><pub-id pub-id-type="pmcid">PMC4036332</pub-id></element-citation></ref><ref id="B32-vaccines-12-00484"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bateman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Finn</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Wiedmer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Biegert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soding</surname><given-names>J.</given-names></name></person-group><article-title>Phospholipid Scramblases and Tubby-Like Proteins Belong to a New Superfamily of Membrane Tethered Transcription Factors</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><fpage>159</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btn595</pub-id><pub-id pub-id-type="pmid">19010806</pub-id><pub-id pub-id-type="pmcid">PMC2639001</pub-id></element-citation></ref><ref id="B33-vaccines-12-00484"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haase</surname><given-names>S.</given-names></name><name name-style="western"><surname>Condron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cherkaoui</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gulbis</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Baum</surname><given-names>J.</given-names></name></person-group><article-title>Identification and Characterisation of a Phospholipid Scramblase in the Malaria Parasite <italic toggle="yes">Plasmodium falciparum</italic></article-title><source>Mol. Biochem. Parasitol.</source><year>2021</year><volume>243</volume><elocation-id>111374</elocation-id><pub-id pub-id-type="doi">10.1016/j.molbiopara.2021.111374</pub-id><pub-id pub-id-type="pmid">33974939</pub-id><pub-id pub-id-type="pmcid">PMC8202325</pub-id></element-citation></ref><ref id="B34-vaccines-12-00484"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dal Col</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lamberti</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Nigro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Casolaro</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fratta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Steffan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Montico</surname><given-names>B.</given-names></name></person-group><article-title>Phospholipid Scramblase 1: A Protein with Multiple Functions via Multiple Molecular Interactors</article-title><source>Cell Commun. Signal</source><year>2022</year><volume>20</volume><fpage>78</fpage><pub-id pub-id-type="doi">10.1186/s12964-022-00895-3</pub-id><pub-id pub-id-type="pmid">35650588</pub-id><pub-id pub-id-type="pmcid">PMC9158361</pub-id></element-citation></ref><ref id="B35-vaccines-12-00484"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gaudet</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Park</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Su</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cheppali</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Cheemarla</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Uchil</surname><given-names>P.D.</given-names></name><etal/></person-group><article-title>PLSCR1 Is a Cell-Autonomous Defence Factor against SARS-CoV-2 Infection</article-title><source>Nature</source><year>2023</year><volume>619</volume><fpage>819</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06322-y</pub-id><pub-id pub-id-type="pmid">37438530</pub-id><pub-id pub-id-type="pmcid">PMC10371867</pub-id></element-citation></ref><ref id="B36-vaccines-12-00484"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanghi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vembar</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Baumgarten</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guizetti</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bryant</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Mattei</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>A.T.R.</given-names></name><name name-style="western"><surname>Renia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Goh</surname><given-names>Y.S.</given-names></name><etal/></person-group><article-title>A Specific PfEMP1 Is Expressed in <italic toggle="yes">P. falciparum</italic> Sporozoites and Plays a Role in Hepatocyte Infection</article-title><source>Cell Rep.</source><year>2018</year><volume>22</volume><fpage>2951</fpage><lpage>2963</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.02.075</pub-id><pub-id pub-id-type="pmid">29539423</pub-id><pub-id pub-id-type="pmcid">PMC5863040</pub-id></element-citation></ref><ref id="B37-vaccines-12-00484"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindner</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Swearingen</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Harupa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vaughan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Sinnis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moritz</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Kappe</surname><given-names>S.H.</given-names></name></person-group><article-title>Total and Putative Surface Proteomics of Malaria Parasite Salivary Gland Sporozoites</article-title><source>Mol. Cell Proteom.</source><year>2013</year><volume>12</volume><fpage>1127</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1074/mcp.M112.024505</pub-id><pub-id pub-id-type="pmcid">PMC3650326</pub-id><pub-id pub-id-type="pmid">23325771</pub-id></element-citation></ref><ref id="B38-vaccines-12-00484"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schopf</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Biebl</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Buchner</surname><given-names>J.</given-names></name></person-group><article-title>The HSP90 Chaperone Machinery</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2017</year><volume>18</volume><fpage>345</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">28429788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrm.2017.20</pub-id></element-citation></ref><ref id="B39-vaccines-12-00484"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corigliano</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Sander</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>E.F.S.</given-names></name><name name-style="western"><surname>Duarte</surname><given-names>V.A.R.</given-names></name><name name-style="western"><surname>Morales</surname><given-names>L.F.M.</given-names></name><name name-style="western"><surname>Angel</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Clemente</surname><given-names>M.</given-names></name></person-group><article-title>Heat Shock Proteins 90 KDa: Immunomodulators and Adjuvants in Vaccine Design against Infectious Diseases</article-title><source>Front. Bioeng. Biotechnol.</source><year>2020</year><volume>8</volume><elocation-id>622186</elocation-id><pub-id pub-id-type="doi">10.3389/fbioe.2020.622186</pub-id><pub-id pub-id-type="pmid">33553125</pub-id><pub-id pub-id-type="pmcid">PMC7855457</pub-id></element-citation></ref><ref id="B40-vaccines-12-00484"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calvert</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Digilio</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Herr</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Coonrod</surname><given-names>S.A.</given-names></name></person-group><article-title>Oolemmal Proteomics&#8212;Identification of Highly Abundant Heat Shock Proteins and Molecular Chaperones in the Mature Mouse Egg and Their Localization on the Plasma Membrane</article-title><source>Reprod. Biol. Endocrinol.</source><year>2003</year><volume>1</volume><elocation-id>27</elocation-id><pub-id pub-id-type="doi">10.1186/1477-7827-1-27</pub-id><pub-id pub-id-type="pmid">12646049</pub-id><pub-id pub-id-type="pmcid">PMC151799</pub-id></element-citation></ref><ref id="B41-vaccines-12-00484"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pires</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Khole</surname><given-names>V.V.</given-names></name></person-group><article-title>A Block in the Road to Fertility: Autoantibodies to Heat-Shock Protein 90-Beta in Human Ovarian Autoimmunity</article-title><source>Fertil. Steril.</source><year>2009</year><volume>92</volume><fpage>1395</fpage><lpage>1409</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2008.08.068</pub-id><pub-id pub-id-type="pmid">19022436</pub-id></element-citation></ref><ref id="B42-vaccines-12-00484"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burnie</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>W.</given-names></name><name name-style="western"><surname>Donohoe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hodgetts</surname><given-names>S.</given-names></name><name name-style="western"><surname>Al-Ghamdi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>R.C.</given-names></name></person-group><article-title>Defining Antibody Targets in <italic toggle="yes">Streptococcus oralis</italic> Infection</article-title><source>Infect. Immun.</source><year>1996</year><volume>64</volume><fpage>1600</fpage><lpage>1608</lpage><pub-id pub-id-type="doi">10.1128/iai.64.5.1600-1608.1996</pub-id><pub-id pub-id-type="pmid">8613367</pub-id><pub-id pub-id-type="pmcid">PMC173968</pub-id></element-citation></ref><ref id="B43-vaccines-12-00484"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>Y.I.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>J.W.</given-names></name></person-group><article-title>Heat Shock Proteins 70 and 90 from <italic toggle="yes">Clonorchis sinensis</italic> Induce Th1 Response and Stimulate Antibody Production</article-title><source>Parasit. Vectors</source><year>2017</year><volume>10</volume><fpage>118</fpage><pub-id pub-id-type="doi">10.1186/s13071-017-2026-7</pub-id><pub-id pub-id-type="pmid">28249599</pub-id><pub-id pub-id-type="pmcid">PMC5333430</pub-id></element-citation></ref><ref id="B44-vaccines-12-00484"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denikus</surname><given-names>N.</given-names></name><name name-style="western"><surname>Orfaniotou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wulf</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Monod</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reichard</surname><given-names>U.</given-names></name></person-group><article-title>Fungal Antigens Expressed during Invasive Aspergillosis</article-title><source>Infect. Immun.</source><year>2005</year><volume>73</volume><fpage>4704</fpage><lpage>4713</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.8.4704-4713.2005</pub-id><pub-id pub-id-type="pmid">16040983</pub-id><pub-id pub-id-type="pmcid">PMC1201263</pub-id></element-citation></ref><ref id="B45-vaccines-12-00484"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nowalk</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Gilmore</surname><given-names>R.D.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Carroll</surname><given-names>J.A.</given-names></name></person-group><article-title>Serologic Proteome Analysis of <italic toggle="yes">Borrelia burgdorferi</italic> Membrane-Associated Proteins</article-title><source>Infect. Immun.</source><year>2006</year><volume>74</volume><fpage>3864</fpage><lpage>3873</lpage><pub-id pub-id-type="doi">10.1128/IAI.00189-06</pub-id><pub-id pub-id-type="pmid">16790758</pub-id><pub-id pub-id-type="pmcid">PMC1489744</pub-id></element-citation></ref><ref id="B46-vaccines-12-00484"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Protective Immune Responses against Systemic Candidiasis Mediated by Phage-Displayed Specific Epitope of <italic toggle="yes">Candida albicans</italic> Heat Shock Protein 90 in C57BL/6J Mice</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>6065</fpage><lpage>6073</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.05.022</pub-id><pub-id pub-id-type="pmid">16842891</pub-id></element-citation></ref><ref id="B47-vaccines-12-00484"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name></person-group><article-title>Chitosan Hydrogel Loaded with Recombinant Protein Containing Epitope C from HSP90 of <italic toggle="yes">Candida albicans</italic> Induces Protective Immune Responses against Systemic Candidiasis</article-title><source>Int. J. Biol. Macromol.</source><year>2021</year><volume>173</volume><fpage>327</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2021.01.105</pub-id><pub-id pub-id-type="pmid">33482211</pub-id></element-citation></ref><ref id="B48-vaccines-12-00484"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Florens</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>O.</given-names></name><name name-style="western"><surname>Peglar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carucci</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Yates</surname><given-names>J.R.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name></person-group><article-title>Proteomics Approach Reveals Novel Proteins on the Surface of Malaria-Infected Erythrocytes</article-title><source>Mol. Biochem. Parasitol.</source><year>2004</year><volume>135</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.molbiopara.2003.12.007</pub-id><pub-id pub-id-type="pmid">15287581</pub-id></element-citation></ref><ref id="B49-vaccines-12-00484"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Florens</surname><given-names>L.</given-names></name><name name-style="western"><surname>Washburn</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Raine</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Anthony</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Grainger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Moch</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Muster</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sacci</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Tabb</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>A Proteomic View of the <italic toggle="yes">Plasmodium falciparum</italic> Life Cycle</article-title><source>Nature</source><year>2002</year><volume>419</volume><fpage>520</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1038/nature01107</pub-id><pub-id pub-id-type="pmid">12368866</pub-id></element-citation></ref><ref id="B50-vaccines-12-00484"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swearingen</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Lindner</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shears</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Harupa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hopp</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Vaughan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Springer</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Moritz</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Kappe</surname><given-names>S.H.</given-names></name><etal/></person-group><article-title>Interrogating the <italic toggle="yes">Plasmodium</italic> Sporozoite Surface: Identification of Surface-Exposed Proteins and Demonstration of Glycosylation on CSP and TRAP by Mass Spectrometry-Based Proteomics</article-title><source>PLoS Pathog.</source><year>2016</year><volume>12</volume><elocation-id>e1005606</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005606</pub-id><pub-id pub-id-type="pmid">27128092</pub-id><pub-id pub-id-type="pmcid">PMC4851412</pub-id></element-citation></ref><ref id="B51-vaccines-12-00484"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bayih</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Folefoc</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohon</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Eagon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pillai</surname><given-names>D.R.</given-names></name></person-group><article-title>In Vitro and in Vivo Anti-Malarial Activity of Novel Harmine-Analog Heat Shock Protein 90 Inhibitors: A Possible Partner for Artemisinin</article-title><source>Malar. J.</source><year>2016</year><volume>15</volume><fpage>579</fpage><pub-id pub-id-type="doi">10.1186/s12936-016-1625-7</pub-id><pub-id pub-id-type="pmid">27903279</pub-id><pub-id pub-id-type="pmcid">PMC5131496</pub-id></element-citation></ref><ref id="B52-vaccines-12-00484"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahinas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Macmullin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Benedict</surname><given-names>C.</given-names></name><name name-style="western"><surname>Crandall</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pillai</surname><given-names>D.R.</given-names></name></person-group><article-title>Harmine Is a Potent Antimalarial Targeting HSP90 and Synergizes with Chloroquine and Artemisinin</article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>56</volume><fpage>4207</fpage><lpage>4213</lpage><pub-id pub-id-type="doi">10.1128/AAC.00328-12</pub-id><pub-id pub-id-type="pmid">22615284</pub-id><pub-id pub-id-type="pmcid">PMC3421604</pub-id></element-citation></ref><ref id="B53-vaccines-12-00484"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Ribolla</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Jacobs-Lorena</surname><given-names>M.</given-names></name></person-group><article-title>Targeting <italic toggle="yes">Plasmodium</italic> Ligands on Mosquito Salivary Glands and Midgut with a Phage Display Peptide Library</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2001</year><volume>98</volume><fpage>13278</fpage><lpage>13281</lpage><pub-id pub-id-type="doi">10.1073/pnas.241491198</pub-id><pub-id pub-id-type="pmid">11687659</pub-id><pub-id pub-id-type="pmcid">PMC60861</pub-id></element-citation></ref><ref id="B54-vaccines-12-00484"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pancholi</surname><given-names>V.</given-names></name></person-group><article-title>Multifunctional Alpha-Enolase: Its Role in Diseases</article-title><source>Cell Mol. Life Sci.</source><year>2001</year><volume>58</volume><fpage>902</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1007/PL00000910</pub-id><pub-id pub-id-type="pmid">11497239</pub-id><pub-id pub-id-type="pmcid">PMC11337373</pub-id></element-citation></ref><ref id="B55-vaccines-12-00484"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>X.R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Preventing <italic toggle="yes">Candida albicans</italic> from Subverting Host Plasminogen for Invasive Infection Treatment</article-title><source>Emerg. Microbes Infect.</source><year>2020</year><volume>9</volume><fpage>2417</fpage><lpage>2432</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1840927</pub-id><pub-id pub-id-type="pmid">33115324</pub-id><pub-id pub-id-type="pmcid">PMC7646593</pub-id></element-citation></ref><ref id="B56-vaccines-12-00484"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussain</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kohler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>K.</given-names></name></person-group><article-title>Enolase of <italic toggle="yes">Staphylococcus lugdunensis</italic> Is a Surface-Exposed Moonlighting Protein That Binds to Extracellular Matrix and the Plasminogen/Plasmin System</article-title><source>Front. Microbiol.</source><year>2022</year><volume>13</volume><elocation-id>837297</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.837297</pub-id><pub-id pub-id-type="pmid">35308335</pub-id><pub-id pub-id-type="pmcid">PMC8928124</pub-id></element-citation></ref><ref id="B57-vaccines-12-00484"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Evaluation of the Protective Efficacy of Six Major Immunogenic Proteins of <italic toggle="yes">Mycoplasma synoviae</italic></article-title><source>Front. Vet. Sci.</source><year>2023</year><volume>10</volume><fpage>1334638</fpage><pub-id pub-id-type="doi">10.3389/fvets.2023.1334638</pub-id><pub-id pub-id-type="pmid">38239753</pub-id><pub-id pub-id-type="pmcid">PMC10794622</pub-id></element-citation></ref><ref id="B58-vaccines-12-00484"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>You</surname><given-names>M.J.</given-names></name></person-group><article-title>Efficacy of Recombinant Enolase as a Candidate Vaccine against <italic toggle="yes">Haemaphysalis longicornis</italic> Tick Infestation in Mice</article-title><source>Parasites Hosts Dis.</source><year>2023</year><volume>61</volume><fpage>439</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.3347/PHD.23075</pub-id><pub-id pub-id-type="pmid">38043539</pub-id><pub-id pub-id-type="pmcid">PMC10693968</pub-id></element-citation></ref><ref id="B59-vaccines-12-00484"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quiroz-Castaneda</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Aguilar-Diaz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Amaro-Estrada</surname><given-names>I.</given-names></name></person-group><article-title>An Alternative Vaccine Target for Bovine Anaplasmosis Based on Enolase, a Moonlighting Protein</article-title><source>Front. Vet. Sci.</source><year>2023</year><volume>10</volume><fpage>1225873</fpage><pub-id pub-id-type="doi">10.3389/fvets.2023.1225873</pub-id><pub-id pub-id-type="pmid">37808115</pub-id><pub-id pub-id-type="pmcid">PMC10556744</pub-id></element-citation></ref><ref id="B60-vaccines-12-00484"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diaz-Hernandez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gonzalez-Vazquez</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Arce-Fonseca</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rodriguez-Morales</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cedillo-Ramirez</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Carabarin-Lima</surname><given-names>A.</given-names></name></person-group><article-title>Consensus Enolase of <italic toggle="yes">Trypanosoma cruzi</italic>: Evaluation of Their Immunogenic Properties Using a Bioinformatics Approach</article-title><source>Life</source><year>2022</year><volume>12</volume><elocation-id>746</elocation-id><pub-id pub-id-type="doi">10.3390/life12050746</pub-id><pub-id pub-id-type="pmid">35629412</pub-id><pub-id pub-id-type="pmcid">PMC9148029</pub-id></element-citation></ref><ref id="B61-vaccines-12-00484"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franco-Serrano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cedano</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perez-Pons</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Mozo-Villarias</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pi&#241;ol</surname><given-names>J.</given-names></name><name name-style="western"><surname>Amela</surname><given-names>I.</given-names></name><name name-style="western"><surname>Querol</surname><given-names>E.</given-names></name></person-group><article-title>A Hypothesis Explaining Why So Many Pathogen Virulence Proteins Are Moonlighting Proteins</article-title><source>Pathog. Dis.</source><year>2018</year><volume>76</volume><fpage>fty046</fpage><pub-id pub-id-type="doi">10.1093/femspd/fty046</pub-id><pub-id pub-id-type="pmid">29718264</pub-id><pub-id pub-id-type="pmcid">PMC5989596</pub-id></element-citation></ref><ref id="B62-vaccines-12-00484"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langowski</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Bitzer</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Genito</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Schrader</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Soto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hadiwidjojo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Optimization of a <italic toggle="yes">Plasmodium falciparum</italic> Circumsporozoite Protein Repeat Vaccine Using the Tobacco Mosaic Virus Platform</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>3114</fpage><lpage>3122</lpage><pub-id pub-id-type="doi">10.1073/pnas.1911792117</pub-id><pub-id pub-id-type="pmid">31988134</pub-id><pub-id pub-id-type="pmcid">PMC7022184</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="vaccines-12-00484-t001" orientation="portrait"><object-id pub-id-type="pii">vaccines-12-00484-t001_Table 1</object-id><label>Table 1</label><caption><p>Major genetic characteristics of <italic toggle="yes">P. falciparum</italic> ligand genes as malaria vaccine antigens. Genetic variations of parasite proteins were identified with NS-SNPs. Each NS-SNP is denoted for location, amino acid change, and percent of the minor allele among all sequenced strains (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://plasmodb.org">https://plasmodb.org</uri> (accessed on 28 March 2024)). The maximum % identity between parasites and all human isoforms was determined.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Ligand</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1"><italic toggle="yes">P. falciparum</italic> Gene</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Human Gene</th></tr><tr><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"># Gene, Isoforms</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Amino Acids</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Genetic Variation</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"># Gene, Isoforms</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Maximum Identity (%)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS-SNPs (%)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strains</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">GAPDH</td><td align="center" valign="middle" rowspan="1" colspan="1">1, 1</td><td align="center" valign="middle" rowspan="1" colspan="1">337</td><td align="center" valign="middle" rowspan="1" colspan="1">140Q-K (33)</td><td align="center" valign="middle" rowspan="1" colspan="1">275</td><td align="center" valign="middle" rowspan="1" colspan="1">1, 2</td><td align="center" valign="middle" rowspan="1" colspan="1">64</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLSCR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">275</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50S-N (1&gt;), 52M-I (1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">301</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5, 10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSP90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">745</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58A-S (2), 229G-R (4), 231R-E (3), 233G-E (1), 235E-G (6), 239K-E (25), 256N-K (1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">301</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2, 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enolase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">446</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">301V-I (1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">300</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4, 10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-12-00484-t002" orientation="portrait"><object-id pub-id-type="pii">vaccines-12-00484-t002_Table 2</object-id><label>Table 2</label><caption><p>In silico prediction of linear B-cell epitope peptides for searching parasite-specific peptides in each <italic toggle="yes">P. falciparum</italic> ligand protein. Percent identity denotes the maximum identity between parasite and human protein orthologs. Parasite epitope peptides no shorter than eight amino acids and are listed on no higher identity than 60%. B-cell epitopes were predicted using <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://tools.iedb.org/bcell/">http://tools.iedb.org/bcell/</uri> (accessed on 28 March 2024).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ligand</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Position</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Peptide Sequence</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">% Identity</th></tr></thead><tbody><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">GAPDH</td><td align="left" valign="middle" rowspan="1" colspan="1">102&#8211;111</td><td align="left" valign="middle" rowspan="1" colspan="1">FLTKELASSH</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">189&#8211;199</td><td align="left" valign="middle" rowspan="1" colspan="1">VDGPSKGGKDW</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">283&#8211;292</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EVVSQDFVHD</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">PLSCR</td><td align="left" valign="middle" rowspan="1" colspan="1">5&#8211;26</td><td align="left" valign="middle" rowspan="1" colspan="1">NIHMQPNINYSYRNPNMYNMNY</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">35&#8211;43</td><td align="left" valign="middle" rowspan="1" colspan="1">QQQMQLFVN</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72&#8211;79</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MGFKLDFN</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">HSP90</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">156&#8211;169</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FTVTKDETNEKLGR</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">211&#8211;340</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RQNEKEITASEEEEGEGEGEREGEEEEEKKKKTGEDKNADESKEENEDEEKKEDNEEDDNKTDHPKVEDVTEELENAEKKKKEKRKKKIHTVEHEWEELNKQKPLWMRKPEEVTNEEYASFYKSLTNDWE</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">562&#8211;590</td><td align="left" valign="middle" rowspan="1" colspan="1">CCTKEGLDIDDSEEAKKDFETLKAEYEGL</td><td align="left" valign="middle" rowspan="1" colspan="1">48</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">716&#8211;742</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SIDEEENNDIDLPPLEETVDATDSKME</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Enolase</td><td align="left" valign="middle" rowspan="1" colspan="1">83&#8211;90</td><td align="left" valign="middle" rowspan="1" colspan="1">NCTEQKKI</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">99&#8211;112</td><td align="left" valign="middle" rowspan="1" colspan="1">DGSKNEWGWSKSKL</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">142&#8211;150</td><td align="left" valign="middle" rowspan="1" colspan="1">QLAGKKSDQ</td><td align="left" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">260&#8211;290</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">YNSENKTYDLDFKTPNNDKSLVKTGAQLVDL</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>